

Imugene names Dr. Anton Uvarov as new Non-Executive Director

Melbourne, Australia, 5 January 2016: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce that Dr. Anton Uvarov has joined its Board as a Non-Executive Director.

Dr. Uvarov, who lives in Perth, WA, brings to Imugene's Board a deep knowledge of the global biotechnology industry, gained initially in academia, then in investment banking as an analyst covering the US biotech sector, and more recently in various bio-entrepreneurial efforts in Australia.

Paul Hopper, Executive Chairman of Imugene, commented 'I am very pleased to have Anton Uvarov as part of Team Imugene. I expect that Anton's scientific background as well as his understanding of how development-stage biotech companies build shareholder value will be important to Imugene as we move our HER-Vaxx cancer immunotherapy to the next stage of clinical development in 2016'.

Currently Dr Uvarov serves as a Non-Executive Director of Actinogen Medical (ASX: ACW). Prior to moving to Australia Dr Uvarov worked for two years in the US healthcare research team at Citigroup Global Markets covering small and mid-cap biotechnology companies.

Dr Uvarov conducted his doctoral research at the Institute of Cardiovascular Sciences in Canada to understand the molecular mechanisms of angiogenesis and its role in cancer biology. Dr Uvarov holds a PhD degree in Biochemistry and Medical Genetics from the University of Manitoba, Canada and an MBA degree from the University of Calgary, Canada.

About Imugene and HER-Vaxx

Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Imugene's lead product is HER-Vaxx, a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer. For further information, please visit www.imugene.com. Sign up to follow @TeamImugene on Twitter at <http://www.twitter.com/TeamImugene>.

For further information please contact:

Imugene:

Leslie Chong, Chief Operating Officer

Tel: +61 458 040 433 (Australia), leslie.chong@imugene.com

Paul Hopper, Executive Chairman

Tel: +61 406 671 515 (Australia), receptogen@earthlink.net

Media:

Rudi Michelson, Monsoon Communications

Tel: +61 3 9620 3333, rudim@monsoon.com.au